Current Landscape of Advanced and Metastatic Renal Cell Carcinoma Management
The first decade of the new millennium witnessed a revolution in the management of advanced renal cell carcinoma (aRCC), thanks to the approval of therapeutic agents targeting the VEGF and mTOR pathways. These targeted therapies transformed the treatment landscape of aRCC and highlighted the success of translational medicine. The arrival of the following decade brought with it clinical trials demonstrating efficacy of immune-oncology (IO) agents in metastatic renal cell carcinoma (mRCC). These trials led to the establishment of second-/third-line roles of IO in mRCC, first as monotherapy and, later, as combinations with other IO agents blocking various immune pathways (ipilimumab/nivolumab).
Source: Urologic Clinics of North America - Category: Urology & Nephrology Authors: William C. Huang, Ezequiel Becher Tags: Preface Source Type: research
More News: Cancer & Oncology | Carcinoma | Clinical Trials | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology | Yervoy